LONDON, February 1, 2018 /PRNewswire/ --
Forecasts and Analysis by Therapeutic Class (Oncology, Alimentary Tract & Metabolism, Hormonal Disorders & Haematology, Neuroscience, Respiratory, Cardiovascular, Nephrology and Ophthalmology), Drug Class (Biologic, Small Molecule) & by Region Plus Analysis of Leading Companies
• Do you need definitive Orphan Drugs market data?
• Succinct Orphan Drugs market analysis?
• Technological insight?
• Actionable business recommendations?
Read on to discover how this definitive report can transform your own research and save you time.
The Global Orphan Drugs market shows immense potential to grow in the future, growing in line with some emerging trends. One such trend is the increasing strategic partnerships in a move to introduce or diversify product portfolios pertaining to drugs. Another trend is advances in biomedical sciences and introduction of nanotechnologies in the global pharmaceutical market, which are revolutionising the development of medicines.
Lastly, the study of the pathogenesis of disease at genetic and molecular level studies have led to the discovery of new targets for therapy and producing disease modifying drugs.
• 149 quantitative tables, charts, and graphs across 173 pages
• Global Orphan Drugs market outlook and analysis from 2018-2028
• Global Orphan Drugs submarket forecasts and analysis from 2018-2028
• Alimentary Tract & Metabolism
• Hormonal Disorders & Haematology
• Key National Orphan Drugs market forecasts 2018-2028
• US forecast 2018-2028
• Germany forecast 2018-2028
• UK forecast 2018-2028
• France forecast 2018-2028
• Italy forecast 2018-2028
• Spain forecast 2018-2028
• Japan forecast 2018-2028
• Singapore forecast 2018-2028
• South Korea forecast 2018-2028
• Brazil forecast 2018-2028
• Russia forecast 2018-2028
• China forecast 2018-2028
• Brazil forecast 2018-2028
Key questions answered
• What does the future hold for the Pharmaceutical industry with regards to Orphan Drugs
• Where should you target your business strategy?
• Which applications should you focus upon?
• Which disruptive technologies should you invest in?
• Which companies should you form strategic alliances with?
• Which company is likely to success and why?
• What business models should you adopt?
• What industry trends should you be aware of?
• Leading Pharmaceutical companies
• R&D staff
• Business development managers
To request a report overview of this report please contact Sara Peerun at firstname.lastname@example.org (+44-(0)-20-7336-6100) or refer to our website: https://www.visiongain.com/Report/2113/Orphan-Drugs-Market-Report-2018-2028
Companies Mentioned in the Report
Advanced Accelerator Applications
Amicus Therapeutics UK Ltd
Arbor Pharmaceuticals LLC
Baxalta Innovations GmbH
Bio Products Laboratory Ltd
Biogen Idec Ltd
Boehringer Ingelheim Pharmaceuticals, Inc.
Clovis Oncology Inc
CSL Behring GmbH
Eli Lilly And Company
Eli Lilly Nederland B.V.
Elusys Therapeutics, Inc
GlaxoSmithKline Trading Services Limited
Intercept Pharmaceuticals Inc
Janssen Pharmaceuticals Inc
Janssen-Cilag International N.V.
Jazz Pharmaceuticals Inc
Mitsubishi Tanabe Pharma Corporation
Nova Laboratories Limited
Novo Nordisk Inc.
NX Development Corporation
Onyx Therapeutics Inc.
Pierre Fabre Dermatologie
Rare Disease Therapeutics
Swedish Orphan Biovitrum AB
United Therapeutics Corporation
To see a report overview please email Sara Peerun on email@example.com